Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company`s products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Website: transcodetherapeutics.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 50% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -270.4% (LTM)

Entry Point: Share price is 566.7% higher than minimum and 87.3% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: RNAZ
Share price, USD:  (+16.0%)0.82
year average price 1.1013  


year start price 0.3159 2023-05-08

max close price 6.1900 2023-05-23

min close price 0.1230 2024-01-10

current price 0.8200 2024-05-06
Common stocks: 3 157 194

Dividend Yield:  0.0%
Last revenue growth (y/y):  ---
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 3
Net Debt ($m): -17
EV (Enterprise Value): -14
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-01-19Zacks Investment Research

TransCode (RNAZ) Down 50% on Issue of New Common Stock

2023-10-27InvestorPlace

Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?

2023-09-26InvestorPlace

Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?

2023-09-26Proactive Investors

Transcode Therapeutic stock whipsaws lower after cut price placing

2023-09-25InvestorPlace

Why Is TransCode Therapeutics (RNAZ) Stock Up 240% Today?

2023-09-25Proactive Investors

TransCode Therapeutics stock skyrockets on positive brain cancer trial results

2023-07-10Zacks Investment Research

TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

2023-04-06GlobeNewsWire

TransCode Therapeutics to present at AACR Annual Meeting 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol RNAZ RNAZ RNAZ RNAZ RNAZ RNAZ RNAZ
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-01 2023-09-30 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-15
acceptedDate 2024-04-01 17:10:47 2023-09-29 20:00:00 2023-08-14 16:31:00 2023-05-15 16:20:58 2023-03-31 16:06:09 2022-11-14 16:36:52 2022-08-15 16:06:59
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 0 0
costOfRevenue 140 173 138 783 137 591 0 0 0 0
grossProfit -140 173 -138 783 -137 591 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 3M 3M 3M 3M 3M 3M 3M
generalAndAdministrativeExpenses 695 408 2M 2M 2M 3M 2M 2M
sellingAndMarketingExpenses -140 173 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 555 235 2M 2M 2M 3M 2M 2M
otherExpenses 0 0 0 -79 409 -383 767 -654 949 0
operatingExpenses 4M 5M 4M 5M 5M 4M 5M
costAndExpenses 4M 5M 4M 5M 5M 4M 0
interestIncome 137.000 131.000 246.000 4770.000 9636.000 9001.000 1331.000
interestExpense 55 899 0 0 -84 179 13M 9001.000 0
depreciationAndAmortization 140 173 138 783 137 591 179 608 422 908 688 752 44.277
ebitda -4M -5M -4M -5M -5M -4M -5M
ebitdaratio 0 0 0 0 0 0 0
operatingIncome -4M -5M -5M -5M -6M -5M 0
operatingIncomeRatio 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -28 517 27 572 789 183 84 179 393 403 663 950 0
incomeBeforeTax -4M -5M -4M -5M -5M -4M -5M
incomeBeforeTaxRatio 0 0 0 0 0 0 0
incomeTaxExpense -3.000 27 441 788 937 -4770.000 13M -663 950 0
netIncome -4M -5M -4M -5M -18M -4M -5M
netIncomeRatio 0 0 0 0 0 0 0
eps -6.510 -67.150 -131.610 -0.330 -3.050 -0.280 -0.360
epsdiluted -6.510 -67.150 -131.610 -0.330 -3.050 -0.280 -0.360
weightedAverageShsOut 627 448 78 929 32 988 14M 6M 13M 13M
weightedAverageShsOutDil 627 448 78 929 32 988 14M 6M 13M 13M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol RNAZ RNAZ RNAZ RNAZ RNAZ RNAZ RNAZ
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-01 2023-09-30 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-15
acceptedDate 2024-04-01 17:10:47 2023-09-29 20:00:00 2023-08-14 16:31:00 2023-05-15 16:20:58 2023-03-31 16:06:09 2022-11-14 16:36:52 2022-08-15 16:06:59
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 3M 7M 4M 2M 5M 9M 13M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 3M 7M 4M 2M 5M 9M 13M
netReceivables 0 0 0 0 360 229 487 879 0
inventory 0 0 0 0 554 330 0 0
otherCurrentAssets 2M 1M 759 555 2M 1M 2M 482 398
totalCurrentAssets 4M 9M 5M 4M 7M 12M 14M
propertyPlantEquipmentNet 602 401 742 574 876 752 996 234 208 581 209 871 234 673
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 111 855 111 856 111 856 247 653 0 235 817 0
totalNonCurrentAssets 714 256 854 430 988 608 1M 208 581 445 688 234 673
otherAssets 1.000 0 0 0 0 0 0
totalAssets 5M 10M 6M 6M 8M 12M 14M
accountPayables 2M 5M 3M 0 4M 0 2M
shortTermDebt 412 280 404 928 397 641 390 419 0 0 0
taxPayables 0 0 0 0 0 0 0
deferredRevenue 27 057 54 306 81 747 0 0 23 538 23 538
otherCurrentLiabilities 719 387 283 762 0 5M 0 4M 0
totalCurrentLiabilities 3M 6M 4M 5M 4M 4M 2M
longTermDebt 38 291 189 766 265 652 377 813 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0.000 -0.000 0 0 4M -23 538 0
totalNonCurrentLiabilities 38 291 189 766 265 652 377 813 4M 23 538 0
otherLiabilities 0 0 0 0 -4M -23 538 0
capitalLeaseObligations 38 291 594 694 663 293 768 232 0 0 0
totalLiabilities 4M 6M 4M 6M 4M 4M 2M
preferredStock 0 0 0 0 0 0 0
commonStock 63.000 1069.000 195.000 1582.000 1298.000 1298.000 1298.000
retainedEarnings -46M -42M -37M -33M -28M -23M -18M
accumulatedOtherComprehensiveIncomeLoss 0.000 0 0 0 0 0 0
othertotalStockholdersEquity 48M 47M 39M 32M 31M 31M 31M
totalStockholdersEquity 2M 4M 2M -236 792 3M 8M 12M
totalEquity 2M 4M 2M -236 792 3M 8M 12M
totalLiabilitiesAndStockholdersEquity 5M 10M 6M 6M 8M 12M 14M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 5M 10M 6M 6M 8M 12M 14M
totalInvestments 0 0 0 0 0 0 0
totalDebt 450 571 594 694 663 293 768 232 0 0 0
netDebt -2M -7M -3M -854 425 -5M -9M -13M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol RNAZ RNAZ RNAZ RNAZ RNAZ RNAZ RNAZ
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-04-01 2023-09-30 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-15
acceptedDate 2024-04-01 17:10:47 2023-09-29 20:00:00 2023-08-14 16:31:00 2023-05-15 16:20:58 2023-03-31 16:06:09 2022-11-14 16:36:52 2022-08-15 16:06:59
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -4M -5M -4M -5M -5M -4M -8M
depreciationAndAmortization 140 173 138 783 137 591 100 199 29 505 24 802 44 277
deferredIncomeTax -3M 1M -2M 0 -1 309M 0 0
stockBasedCompensation 310 314 392 331 175 484 158 760 130 555 105 602 159 111
changeInWorkingCapital -2M 1M -363 124 44 424 954 272 -262 822 617 632
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables -2M 2M -2M 575 982 609 452 2M -799 177
otherWorkingCapital 61 264 -696 059 1M -531 558 344 820 -2M 0
otherNonCashItems 3M -1M 2M 0 1 309M 0 0
netCashProvidedByOperatingActivities -6M -4M -4M -5M -4M -4M -7M
investmentsInPropertyPlantAndEquipment 0 -4606.000 -18 107 -12 896 -28 215 0 0
acquisitionsNet 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 -72 673
netCashUsedForInvestingActivites 0 -4606.000 -18 107 -12 896 -28 215 0 -72 673
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 978 153 7M 6M 1M 6M 0 0
commonStockRepurchased 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 978.153 135 797 -135 797 0 -6M -225 817 5983.011
netCashUsedProvidedByFinancingActivities 978 153 7M 6M 1M 225 817 -225 817 5983.011
effectOfForexChangesOnCash 0 0 0 0 0 0 0
netChangeInCash -5M 4M 2M -3M -4M -5M -3M
cashAtEndOfPeriod 3M 7M 4M 2M 5M 9M 13M
cashAtBeginningOfPeriod 7M 4M 2M 5M 9M 13M 17M
operatingCashFlow -6M -4M -4M -5M -4M -4M -7M
capitalExpenditure 0 -4606.000 -18 107 -12 896 -28 215 0 0
freeCashFlow -6M -4M -4M -5M -4M -4M -7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-04-03 13:10 ET
TransCode Therapeutics Reports 2023 Results; Provides Business Update
2024-03-28 12:30 ET
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
2024-03-11 13:00 ET
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
2024-02-20 13:00 ET
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
2024-01-31 21:05 ET
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
2024-01-29 13:30 ET
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
2024-01-22 21:45 ET
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
2024-01-18 18:27 ET
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
2024-01-12 21:05 ET
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
2024-01-11 13:00 ET
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
2024-01-04 13:05 ET
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
2023-12-12 13:30 ET
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
2023-12-05 14:00 ET
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
2023-12-04 21:10 ET
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-11-30 19:53 ET
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-11-14 21:30 ET
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
2023-10-30 20:33 ET
TransCode Therapeutics Withdraws Public Offering
2023-10-27 12:00 ET
Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions
2023-10-26 20:19 ET
TransCode Therapeutics Announces Public Offering of Common Stock
2023-10-26 12:00 ET
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
2023-10-24 12:00 ET
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138
2023-10-16 12:00 ET
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA
2023-09-28 20:02 ET
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
2023-09-26 00:01 ET
TransCode Therapeutics Announces Pricing of $8 Million Public Offering
2023-09-25 12:30 ET
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
2023-08-23 12:00 ET
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial
2023-08-14 20:45 ET
TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update
2023-07-31 11:00 ET
TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
2023-07-13 16:43 ET
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi
2023-07-05 11:00 ET
TransCode Therapeutics CEO Letter to Shareholders
2023-06-28 19:49 ET
TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate
2023-06-22 11:00 ET
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
2023-06-09 20:05 ET
TransCode Therapeutics Announces Closing of $7 Million Public Offering
2023-06-06 21:29 ET
TransCode Therapeutics Announces Pricing of $7 Million Public Offering
2023-06-06 20:01 ET
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma
2023-05-22 11:00 ET
TransCode Therapeutics Announces 1-for-20 Reverse Stock Split
2023-04-27 11:00 ET
TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial
2023-04-26 12:00 ET
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
2023-04-14 11:00 ET
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
2023-04-06 11:00 ET
TransCode Therapeutics to present at AACR Annual Meeting 2023
2023-04-05 11:00 ET
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
2023-04-05 01:00 ET
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
2023-04-03 12:00 ET
TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock
2023-03-31 20:01 ET
TransCode Therapeutics Reports 2022 Results; Provides Business Update
2023-02-28 12:00 ET
TransCode Therapeutics Announces Orphan Drug Designation Status for TTX-MC138 for Treatment of Pancreatic Cancer
2023-02-22 13:00 ET
TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment
2023-02-16 13:00 ET
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
2023-01-31 21:05 ET
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
2022-12-29 13:00 ET
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
2022-12-06 21:20 ET
TransCode Therapeutics Announces Withdrawal of Registration Statement
2022-11-30 12:00 ET
TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors
2022-11-14 21:15 ET
TransCode Therapeutics Reports Third Quarter 2022 Results; Provides Business Update
2022-11-09 12:00 ET
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma
2022-11-07 13:00 ET
TransCode Therapeutics to Present at Sidoti Virtual Investor Conference
2022-10-26 11:00 ET
TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma
2022-10-19 12:00 ET
TransCode Therapeutics: Invitation to The ThinkEquity Conference
2022-10-13 11:00 ET
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
2022-09-27 12:00 ET
TransCode Therapeutics to Participate at the Chardan 6th Annual Genetic Medicines Conference
2022-09-08 12:00 ET
TransCode Therapeutics Appoints MicroRNA Pioneer, Dr. Frank Slack, to its Advisory Board
2022-08-15 20:15 ET
TransCode Therapeutics Reports Second Quarter 2022 Results; Provides Business Update
2022-08-02 11:00 ET
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
2022-07-11 20:05 ET
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
2022-06-09 13:00 ET
TransCode Therapeutics to Participate at BIO International Convention
2022-06-01 13:00 ET
TransCode Therapeutics Receives National Institutes of Health (NIH) Notice of Award
2022-05-20 13:00 ET
TransCode Therapeutics To Participate at H.C. Wainwright Global Investment Conference
2022-05-19 13:00 ET
TransCode Therapeutics Acquires Option for Radiotheranostic Technology
2022-05-16 12:30 ET
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
2022-04-13 13:00 ET
TransCode Therapeutics’ CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
2022-03-31 20:30 ET
TransCode Therapeutics Reports 2021 Results; Provides Business Update
2022-03-25 16:00 ET
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®
2022-03-23 13:00 ET
TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders
2022-02-14 14:00 ET
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
2022-02-10 14:45 ET
CORRECTION --TransCode Therapeutics
2022-02-10 13:30 ET
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
2022-01-06 20:17 ET
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
2021-12-07 00:10 ET
TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference
2021-11-15 21:01 ET
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results
2021-11-09 12:30 ET
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit
2021-09-30 20:01 ET
TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer
2021-09-23 11:30 ET
TransCode Therapeutics Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer
2021-08-23 20:01 ET
TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
2021-08-05 11:30 ET
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138
2021-07-13 20:30 ET
TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Over-allotment Option
2021-07-08 22:34 ET
TransCode Therapeutics, Inc. Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2024-04-05 00:00 ET
TransCode Therapeutics, Inc. published news for 2024 q1
SEC form 8
2024-04-05 00:00 ET
TransCode Therapeutics, Inc. published news for 2024 q1
SEC form 10
2024-04-01 00:00 ET
TransCode Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-01-16 00:00 ET
TransCode Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-01-16 00:00 ET
TransCode Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-01-16 00:00 ET
TransCode Therapeutics, Inc. published news for 2023 q4
SEC form 8
2024-01-16 00:00 ET
TransCode Therapeutics, Inc. published news for 2023 q4
SEC form 10
2023-11-14 00:00 ET
TransCode Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-14 00:00 ET
TransCode Therapeutics, Inc. published news for 2023 q3
SEC form 10
2023-08-14 00:00 ET
TransCode Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-05-22 07:45 ET
TransCode Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-19 16:56 ET
TransCode Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-05-18 09:15 ET
TransCode Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-15 16:20 ET
TransCode Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
TransCode Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-10 17:21 ET
TransCode Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-14 07:19 ET
TransCode Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-10 17:01 ET
TransCode Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-03-31 16:17 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-31 16:14 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 10
2023-03-31 16:06 ET
TransCode Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-31 16:02 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 10
2023-03-31 00:00 ET
TransCode Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-31 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-02-17 08:34 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 8
2023-02-17 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-02-01 16:05 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 8
2023-02-01 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-09 16:15 ET
TransCode Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-30 07:08 ET
TransCode Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-14 16:36 ET
TransCode Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-14 16:18 ET
TransCode Therapeutics, Inc. published news for 2022 q3
SEC form 8
2022-11-14 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
TransCode Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-08-15 16:09 ET
TransCode Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-15 16:06 ET
TransCode Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-15 00:00 ET
TransCode Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-03 16:05 ET
TransCode Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-23 16:01 ET
TransCode Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-05-16 16:03 ET
TransCode Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-16 07:01 ET
TransCode Therapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
TransCode Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-02 16:02 ET
TransCode Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-01 16:00 ET
TransCode Therapeutics, Inc. published news for 2022 q1
SEC form 8
2022-04-01 00:00 ET
TransCode Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-31 11:19 ET
TransCode Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
TransCode Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-11-15 16:03 ET
TransCode Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-15 16:02 ET
TransCode Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
TransCode Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
TransCode Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-09-30 17:13 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-23 16:55 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-23 16:53 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 8
2021-08-23 00:00 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-23 00:00 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-13 17:22 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:54 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:53 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:53 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:53 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:53 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:52 ET
TransCode Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-07-08 21:52 ET
TransCode Therapeutics, Inc. published news for 2021 q2